Shares of Iovance Biotherapeutics (NASDAQ: IOVA) had skyrocketed by 33.8% as of 10:39 a.m. ET Tuesday. The large gain came after the company announced on Friday that the Food and Drug Administration (FDA) had granted accelerated approval for Amtagvi (lefileucel) as a treatment for advanced melanoma.
Resulting from Presidents’ Day holiday, the stock market was closed on Monday. Investors needed to attend until Tuesday to push Iovance’s share price higher.
Iovance also announced on Tuesday morning the pricing of an underwritten offering to issue just over 23 million recent shares for $9.15 per share. That stock sale will generate gross proceeds of around $211 million. A component of the money may be used to support the business launch of Amtagvi.
How big is the FDA approval for Iovance?
It’s hard to overstate just how essential the FDA’s approval of Amtagvi is for Iovance. The company shouldn’t be any longer a clinical-stage biotech — it now has a marketable product. And never just any product: Amtagvi is the first (and up to now, only) individualized T-cell therapy to win a thumbs-up from the FDA to treat a solid tumor.
Iovance may also be evaluating Amtagvi in late-stage clinical studies targeting cervical cancer and non-small cell lung cancer. Analytics company GlobalData projects that Amtagvi will generate annual global sales of nearly $900 million by 2029.
Is Iovance Biotherapeutics stock an outstanding pick to buy now?
With a market cap of nearly $3.2 billion, much of the anticipated growth for Iovance is already priced into the stock. Nevertheless, the company could still have more catalysts on the way in which during which, including potential regulatory approvals for Amtagvi in other countries. I think Iovance stock stays an outstanding pick to buy for aggressive investors.
Do you will have to take a position $1,000 in Iovance Biotherapeutics immediately?
Before you buy stock in Iovance Biotherapeutics, consider this:
The Motley Idiot Stock Advisor analyst team just identified what they consider are the 10 best stocks for investors to buy now… and Iovance Biotherapeutics wasn’t one amongst them. The ten stocks that made the cut could produce monster returns within the approaching years.
Stock Advisor provides investors with an easy-to-follow blueprint for achievement, including guidance on constructing a portfolio, regular updates from analysts, and two recent stock picks every month. The Stock Advisor service has greater than tripled the return of S&P 500 since 2002*.
*Stock Advisor returns as of February 12, 2024
Keith Speights has no position in any of the stocks mentioned. The Motley Idiot has positions in and recommends Iovance Biotherapeutics. The Motley Idiot has a disclosure policy.
Why Iovance Biotherapeutics Stock Is Skyrocketing Today was originally published by The Motley Idiot